Systemic review and meta-analysis of tolerability and safety between different titration regimes of ropinirol dose in the treatment of Parkinson's disease;Revisión sistemática y metaanálisis de la tolerabilidad y seguridad entre diferentes pautas de titulación de la dosis de ropinirol en el tratamiento de la enfermedad de Parkinson

Neurologia

Volumn 22, Issue 10, 2007, Pages 882-894

  Chacón, José ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

Administration and dosage; Adverse effects; Meta analysis; Parkinson's disease; Ropinirole; Titration

Indexed keywords

BROMOCRIPTINE; LEVODOPA; PLACEBO; ROPINIROLE;

AMNESIA; ARTICLE; ATAXIA; CLINICAL TRIAL; CONFUSION; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSTONIA; EDEMA; FATIGUE; HALLUCINATION; HUMAN; INSOMNIA; META ANALYSIS; NAUSEA; ORTHOSTATIC HYPOTENSION; PARASOMNIA; PARKINSON DISEASE; SEXUAL DYSFUNCTION; SOMNOLENCE; SYNCOPE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VERTIGO; VIRUS INFECTION;

ANTIPARKINSON AGENTS; HUMANS; INDOLES; PARKINSON DISEASE;

EID: 38349150064     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Tuite P RJ. Recent developments in the pharmacological treatment of Parkinson's disease. Expert Opin Investig Drugs 2003;12:1335-52.
2. Lambert D, Waters CH, Waters CH. Comparative tolerability of the newer generation antiparkinsonian agents. Drugs Aging 2000;16:55-65.
3. Korczyn AD, Brunt ER, Larsen JP. A 3 year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. Neurology 1999;53:364-70.
4. Bonucelli U. Comparing dopamine agonists in Parkinson's disease. Curr Opin Neurol 2003;16(Suppl. 1):S13-9.
5. Inzelberg R, Schechtman E, Nisipeanu O. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disesase. Drugs Aging 2003;20:847-55.
6. Jost WH. Ropinirole: current status of the studies. J Neurol 2004;251(Suppl. 6):VI/13-8.
7. Murdoch D, Cheer SM, Wagstaff AJ. Management of Parkinson disease: defining the role of ropinirol. En: Disease management and health outcomes. Pennsylvania: Adis International Inc ed Yardley, 2004; p. 39-54.
8. Matheson AJ, Spencer CM. Ropinirole: a review of its use in the management of Parkinson's disease. Drugs 2000;60:115-37.
9. Barclay CL, O'Neil MC, on behalf of the Canadian Ropinirole Group. Comparison of tolerability and efficacy of three ropinirole titration regimens in early PD, 2004. Mov Disord 2000;15(Suppl. 3):642.
10. Glaxo SmithKline. Ficha técnica de Requip, 2002.
11. Delgado M. Revisión sistemática de estudios. Metaanálisis. UD 7. En: Domenech JM, editor. Diseño de estudios sanitarios. Barcelona: Signo, 2002.
12. Einarson TR. Pharmacoeeonomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example. Clin Ther 1997;19:559-69.
13. Alderson P, Green S, Higgins JPT. Cochrane Reviewers' Handbook 4.2.2 (updated March 2004). En: The Cochrane Library. Chichester: Wiley and Sons, 2004.
14. Cochran W. The combination of estimates from different experiments. Biometries 1954:101-29.
15. Adler C, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 1997;49:393-9.
16. Brunt ER, Brooks DJ, Korczyn AD, Montastruc JL, Stocchi F. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. J Neural Transm 2002;109:489-502.
17. Im JH, Ha JH, Cho IS, Lee MC. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study. J Neurol 2003;250:90-6.
18. Korczyn AD, Brooks DJ, Brunt E, Poewe W, Rascol O, Stocchi F, et al. Ropinirole versus bromocriptine in the treatment of early parkinson's disease: a 6-month interim report of a 3 year study. Mov Disord 1998;13:46-51.
19. Lieberman A, Olanow CW, Sethi K, Swanson P, Waters CH, Fahn S, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology 1998;51:1057-62.
20. Rascol O, Brooks DJ, Brunt E, Korczyn AD, Poewe W, Stocchi F, et al. Ropinirole in the treatment of early parkinson's disease: a 6-month interim report of a 5-year Levodopa controlled study. Mov Disord 1998;13:39-45.
21. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101.
22. Brooks D, Abbott RJ, Lees AJ, Martignoni E, Philcox DV, Rascol O, et al. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in parkinson's disease. Clin Neuropharmacol 1998;21:101-7.
23. Müngersdorf M, Sommer U, Sommer M, Reichmann H. High-dose therapy with ropinirole in patients with Parkinson's disease. J Neural Transm 2001;108:1309-17.
24. Hubble J, Koller WC, Atchison P, Taylor AC, Citerone DR, Zussman BD, et al. Linear pharmacokinetic behavior of ropinirole during multiple dosing in patients with Parkinson's disease. J Clin Pharmacol 2000;40:641-6.
25. Cristina S, Zangaglia R, Mancini F, Martignoni E, Nappi G, Pacchetti C. High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias. Clin Neuropharmacol 2003;26:146-50.
26. Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 1996;19:234-45.